Allogene Therapeutics, Inc. NASDAQ:ALLO

Founder-led company

Allogene Therapeutics stock price today

$1.07
-1.11
-51.14%
Financial Health
0
1
2
3
4
5
6
7
8
9

Allogene Therapeutics stock price monthly change

-20.65%
month

Allogene Therapeutics stock price quarterly change

-20.65%
quarter

Allogene Therapeutics stock price yearly change

-31.56%
year

Allogene Therapeutics key metrics

Market Cap
392.08M
Enterprise value
703.51M
P/E
-2.09
EV/Sales
3589.34
EV/EBITDA
-3.13
Price/Sales
3419.86
Price/Book
1.00
PEG ratio
0.09
EPS
-1.79
Revenue
130K
EBITDA
-270.67M
Income
-290.08M
Revenue Q/Q
-57.69%
Revenue Y/Y
-44.44%
Profit margin
-121318.88%
Oper. margin
-121977.04%
Gross margin
0%
EBIT margin
-121977.04%
EBITDA margin
-208214.62%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Allogene Therapeutics stock price history

Allogene Therapeutics stock forecast

Allogene Therapeutics financial statements

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Profit margin
Jun 2023 44K -77.98M -177247.73%
Sep 2023 43K -61.31M -142593.02%
Dec 2023 21K -85.77M -408466.67%
Mar 2024 22K -65M -295454.55%
Allogene Therapeutics, Inc. (NASDAQ:ALLO): Analyst Estimates
Mar 2024 22K -65M -295454.55%
Sep 2025 11.5K -63.77M -554600.68%
Oct 2025 10.63K -64.53M -606801.27%
Dec 2025 10.63K -65.38M -614736.11%
  • Analysts Price target

  • Financials & Ratios estimates

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Debt to assets
Jun 2023 770971000 148.06M 19.21%
Sep 2023 712326000 129.22M 18.14%
Dec 2023 642837000 130.60M 20.32%
Mar 2024 586350000 124.98M 21.32%
Allogene Therapeutics, Inc. (NASDAQ:ALLO): Cash Flow
Jun 2023 -61.85M 17.16M 89.52M
Sep 2023 -55.53M -34.26M 4.28M
Dec 2023 -53.70M 67.46M 155K
Mar 2024 -55.89M 22.13M 1.65M

Allogene Therapeutics alternative data

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Employee count
Sep 2023 359
Oct 2023 359
Nov 2023 359
Dec 2023 359
Jan 2024 359
Feb 2024 359
Apr 2024 232
May 2024 232
Jun 2024 232
Jul 2024 232

Allogene Therapeutics other data

23.55% -53.70%
of ALLO is owned by hedge funds
33.70M -77.27M
shares is hold by hedge funds

Allogene Therapeutics, Inc. (NASDAQ:ALLO): Insider trades (number of shares)
Period Buy Sel
Jan 2024 190 0
May 2024 1724137 11200
Jun 2024 0 18641
Dec 2024 0 18357
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MESSEMER DEBORAH M. director
Common Stock 9,136 $2.18 $19,916
Sale
HUMER FRANZ B director
Common Stock 9,221 $2.16 $19,917
Sale
MESSEMER DEBORAH M. director
Common Stock 18,641 $2.28 $42,483
Sale
HUMER FRANZ B director
Common Stock 11,200 $2.34 $26,186
Purchase
BELLDEGRUN ARIE director
Common Stock 1,724,137 $2.9 $4,999,997
Purchase
PARKER GEOFFREY M. officer: CHIEF FI.. Common Stock 190 $3.6 $683
Sale
MESSEMER DEBORAH M. director
Common Stock 18,640 $2.7 $50,309
Sale
MAYO STEPHEN director
Common Stock 10,000 $4.29 $42,860
Sale
BHAVNAGRI VEER officer: General .. Common Stock 3,000 $6.85 $20,550
Sale
BHAVNAGRI VEER officer: General .. Common Stock 3,000 $7.04 $21,120
Patent
Application
Filling date: 4 Mar 2022 Issue date: 8 Sep 2022
Application
Filling date: 28 Jan 2022 Issue date: 11 Aug 2022
Application
Filling date: 3 Feb 2022 Issue date: 4 Aug 2022
Application
Filling date: 8 Apr 2022 Issue date: 28 Jul 2022
Application
Filling date: 21 Dec 2021 Issue date: 21 Jul 2022
Application
Filling date: 14 Dec 2021 Issue date: 16 Jun 2022
Grant
Filling date: 31 Oct 2018 Issue date: 10 May 2022
Application
Filling date: 26 Jul 2021 Issue date: 3 Feb 2022
Application
Filling date: 21 Jul 2021 Issue date: 27 Jan 2022
Application
Filling date: 24 Feb 2021 Issue date: 26 Aug 2021
Monday, 16 December 2024
globenewswire.com
Thursday, 12 December 2024
globenewswire.com
Monday, 2 December 2024
zacks.com
Monday, 25 November 2024
zacks.com
Tuesday, 19 November 2024
globenewswire.com
Monday, 18 November 2024
globenewswire.com
Friday, 8 November 2024
zacks.com
Thursday, 7 November 2024
seekingalpha.com
globenewswire.com
globenewswire.com
Tuesday, 5 November 2024
globenewswire.com
Thursday, 31 October 2024
zacks.com
Wednesday, 30 October 2024
globenewswire.com
Wednesday, 2 October 2024
gurufocus.com
Monday, 30 September 2024
seekingalpha.com
globenewswire.com
Tuesday, 24 September 2024
businesswire.com
Monday, 16 September 2024
prnewswire.com
Saturday, 7 September 2024
247wallst.com
Friday, 6 September 2024
zacks.com
Monday, 26 August 2024
seekingalpha.com
Saturday, 10 August 2024
seekingalpha.com
Thursday, 8 August 2024
zacks.com
globenewswire.com
investorplace.com
Wednesday, 7 August 2024
globenewswire.com
Wednesday, 31 July 2024
globenewswire.com
Monday, 1 July 2024
globenewswire.com
Thursday, 20 June 2024
globenewswire.com
Wednesday, 12 June 2024
seekingalpha.com
  • What's the price of Allogene Therapeutics stock today?

    One share of Allogene Therapeutics stock can currently be purchased for approximately $1.07.

  • When is Allogene Therapeutics's next earnings date?

    Unfortunately, Allogene Therapeutics's (ALLO) next earnings date is currently unknown.

  • Does Allogene Therapeutics pay dividends?

    No, Allogene Therapeutics does not pay dividends.

  • How much money does Allogene Therapeutics make?

    Allogene Therapeutics has a market capitalization of 392.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.91% to 95K US dollars.

  • What is Allogene Therapeutics's stock symbol?

    Allogene Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ALLO".

  • What is Allogene Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Allogene Therapeutics?

    Shares of Allogene Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Allogene Therapeutics's key executives?

    Allogene Therapeutics's management team includes the following people:

    • Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 65, pay: $1,260,000)
    • Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Executive Chairman(age: 76, pay: $845,190)
    • Dr. Rafael G. Amado Chief Medical Officer and Executive Vice President of R&D(age: 61, pay: $840,000)
    • Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer(age: 55, pay: $660,000)
    • Dr. Alison Moore Ph.D. Chief Technical Officer(age: 58, pay: $660,000)
    • Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer(age: 42, pay: $646,880)
    • Mr. Joshua A. Kazam Co-Founder & Director(age: 48, pay: $390,000)
  • Is Allogene Therapeutics founder-led company?

    Yes, Allogene Therapeutics is a company led by its founders Dr. David D. Chang M.D., Ph.D., Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. and Mr. Joshua A. Kazam.

  • How many employees does Allogene Therapeutics have?

    As Jul 2024, Allogene Therapeutics employs 232 workers.

  • When Allogene Therapeutics went public?

    Allogene Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 11 Oct 2018.

  • What is Allogene Therapeutics's official website?

    The official website for Allogene Therapeutics is allogene.com.

  • Where are Allogene Therapeutics's headquarters?

    Allogene Therapeutics is headquartered at 210 East Grand Avenue, South San Francisco, CA.

  • How can i contact Allogene Therapeutics?

    Allogene Therapeutics's mailing address is 210 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 04572700.

Allogene Therapeutics company profile:

Allogene Therapeutics, Inc.

allogene.com
Exchange:

NASDAQ

Full time employees:

232

Industry:

Biotechnology

Sector:

Healthcare

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

210 East Grand Avenue
South San Francisco, CA 94080

CIK: 0001737287
ISIN: US0197701065
CUSIP: 019770106